Pharma: Weniger Impfstoffnachfrage – Biontech tief in Verlustzone
Die Nachfrage nach dem einst so begehrten Corona-Impfstoff, der das Unternehmen mal groß machte, geht zurück. Unter dem Strich steht für das erste Halbjahr ein Milliardenverlust. Das hat Folgen.
Mainz - The worldwide lower demand for Covid-19 vaccines has plunged BioNTech into a billion euro loss in the first half of 2026. The German company reported a loss of 1.35 billion euros in the first six months (vs. 802.4 million euros a year earlier), according to the company's announcement. The loss for the second quarter was 820.8 million euros (vs. 386.6 million euros a year earlier).
The revenue in that quarter was significantly lower than the previous year's period, at 105.6 million euros (vs. 260.8 million euros). This further indicates that the existing vaccine stocks in Germany can be used in the vaccination season of 2026. Consequently, BioNTech also expects lower revenue for the entire year of 2026. The Mainz-based company now anticipates revenue between 1.6 and 1.9 billion euros, down from their previous forecast of 2 to 2.3 billion euros.
These changes in the figures have also affected the expected expenditures for research and development for the entire year. BioNTech is prioritizing the development of new products and speaking of 2 to 2.3 billion euros in expenditures, less than their previous range of 2.2 to 2.5 billion euros. They explained that they would be adopting a more cost discipline in their operations.
Written by urgent.news from Handelsblatt's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
